Page 3 - Slide 1
P. 3
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1025 Inhibition of Sclerostin With AMG 785 in
Postmenopausal Women With Low Bone Mineral
Density: Phase 2 Trial Results.
McClung M, Grauer A, Boonen S et al.
Session: Concurrent Oral Session 05: John H. Carsten's
Memorial Session for Osteoporosis Treatment◼
Saturday , October 13, 09:30 AM - 09:45 AM◼
Auditorium-Main/Minneapolis Convention Center
Results Abstract Information Additional Notes from
Poster/Presentation*
Conclusions All the 5 regimens of AMG 785 doses
Implications increased Updated/Additional
for Canadian ▪ BMD as compared to placebo at each of Data, Key
Practice Takeaways
the 3 sites at month 12 (p<0.005).
▪ Serum P1NP as compared to baseline at
week 1; serum CTX decreased at week 1
▪ AMG 785 in a dose of 210 mg QM was
associated with largest gains at lumbar
spine and total hip and these effects were
significantly greater as compared to ALN
and TPTD (p<0.0001)
▪ AEs were mild injection-site reactions
▪ The superior effects AMG 785 on lumbar
spine and hip BMD as compared to ALN
and TPTD warrant further investigation of
this sclerostin-neutralizing antibody.
Discussion Points, Key Takeaways
